These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 25450152)

  • 1. Interval debulking surgery following neo-adjuvant chemotherapy for stage IVB ovarian cancer using neutral argon plasma (PlasmaJet™).
    Butler-Manuel S; Lippiatt J; Madhuri TK
    Gynecol Oncol; 2014 Dec; 135(3):622-3. PubMed ID: 25450152
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Experience with PlasmaJet™ in debulking surgery in 87 patients with advanced-stage ovarian cancer.
    Volcke A; Van Nieuwenhuysen E; Han S; Salihi R; Van Gorp T; Vergote I
    J Surg Oncol; 2021 Mar; 123(4):1109-1114. PubMed ID: 33497468
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Primary debulking surgery of the upper abdomen and the diaphragm, with a plasma device surgery system, for advanced ovarian cancer.
    Cordeiro Vidal G; Babin G; Querleu D; Guyon F
    Gynecol Oncol; 2017 Jan; 144(1):223-224. PubMed ID: 27836207
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of systematic pelvic and para-aortic lymphadenectomy in delayed debulking surgery after six neoadjuvant chemotherapy cycles for high-grade serous ovarian carcinoma.
    Lopes A; Genta MLND; da Costa Miranda V; Aranha A; Lopez RVM; Piato DSAM; Anton C; Carvalho FM; Del Pilar Esteves Diz M; Carvalho JP
    J Obstet Gynaecol Res; 2021 Aug; 47(8):2737-2744. PubMed ID: 33998104
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A preoperative low cancer antigen 125 level (≤25.8 mg/dl) is a useful criterion to determine the optimal timing of interval debulking surgery following neoadjuvant chemotherapy in epithelial ovarian cancer.
    Morimoto A; Nagao S; Kogiku A; Yamamoto K; Miwa M; Wakahashi S; Ichida K; Sudo T; Yamaguchi S; Fujiwara K
    Jpn J Clin Oncol; 2016 Jun; 46(6):517-21. PubMed ID: 26977055
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neoadjuvant chemotherapy with six cycles of carboplatin and paclitaxel in advanced ovarian cancer patients unsuitable for primary surgery: Safety and effectiveness.
    da Costa Miranda V; de Souza Fêde ÂB; Dos Anjos CH; da Silva JR; Sanchez FB; da Silva Bessa LR; de Paula Carvalho J; Filho EA; de Freitas D; Del Pilar Estevez Diz M
    Gynecol Oncol; 2014 Feb; 132(2):287-91. PubMed ID: 24333355
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Histopathology predicts clinical outcome in advanced epithelial ovarian cancer patients treated with neoadjuvant chemotherapy and debulking surgery.
    Muraji M; Sudo T; Iwasaki S; Ueno S; Wakahashi S; Yamaguchi S; Fujiwara K; Nishimura R
    Gynecol Oncol; 2013 Dec; 131(3):531-4. PubMed ID: 24096109
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Advances in treatment of epithelial ovarian cancer.
    Kikkawa F; Nawa A; Ino K; Shibata K; Kajiyama H; Nomura S
    Nagoya J Med Sci; 2006 Jan; 68(1-2):19-26. PubMed ID: 16579172
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Only complete tumour resection after neoadjuvant chemotherapy offers benefit over suboptimal debulking in advanced ovarian cancer.
    Vermeulen CKM; Tadesse W; Timmermans M; Kruitwagen RFPM; Walsh T
    Eur J Obstet Gynecol Reprod Biol; 2017 Dec; 219():100-105. PubMed ID: 29078115
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase III randomised clinical trial comparing primary surgery versus neoadjuvant chemotherapy in advanced epithelial ovarian cancer with high tumour load (SCORPION trial): Final analysis of peri-operative outcome.
    Fagotti A; Ferrandina G; Vizzielli G; Fanfani F; Gallotta V; Chiantera V; Costantini B; Margariti PA; Gueli Alletti S; Cosentino F; Tortorella L; Scambia G
    Eur J Cancer; 2016 May; 59():22-33. PubMed ID: 26998845
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Patterns of Recurrence and Clinical Outcome of Patients With Stage IIIC to Stage IV Epithelial Ovarian Cancer in Complete Response After Primary Debulking Surgery Plus Chemotherapy or Neoadjuvant Chemotherapy Followed by Interval Debulking Surgery: An Italian Multicenter Retrospective Study.
    Gadducci A; Cosio S; Zizioli V; Notaro S; Tana R; Panattoni A; Sartori E
    Int J Gynecol Cancer; 2017 Jan; 27(1):28-36. PubMed ID: 27870700
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intensive care admissions among ovarian cancer patients treated with primary debulking surgery and neoadjuvant chemotherapy-interval debulking surgery.
    Pepin K; Bregar A; Davis M; Melamed A; Hinchcliff E; Gockley A; Horowitz N; Del Carmen MG
    Gynecol Oncol; 2017 Dec; 147(3):612-616. PubMed ID: 28988028
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictive value of the age-adjusted Charlston co-morbidity index on peri-operative complications, adjuvant chemotherapy usage and survival in patients undergoing debulking surgery after neo-adjuvant chemotherapy for advanced epithelial ovarian cancer.
    Phillips A; Singh K; Pounds R; Sundar S; Kehoe S; Nevin J; Elattar A; Balega J
    J Obstet Gynaecol; 2017 Nov; 37(8):1070-1075. PubMed ID: 28741395
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neo-adjuvant chemotherapy does not increase the rate of complete resection and does not significantly reduce the morbidity of Visceral-Peritoneal Debulking (VPD) in patients with stage IIIC-IV ovarian cancer.
    Tozzi R; Giannice R; Cianci S; Tardino S; Campanile RG; Gubbala K; Fachechi G; Ferrari F; Martinek I; Soleymani Majd H
    Gynecol Oncol; 2015 Aug; 138(2):252-8. PubMed ID: 26003142
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Optimal surgical cytoreduction of the upper abdomen and the diaphragm for advanced ovarian cancer using PlasmaJet™ energy.
    Seror J; Bats AS; Habchi H; Lécuru F
    Gynecol Oncol; 2016 Feb; 140(2):372-3. PubMed ID: 26621604
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of Neoadjuvant Chemotherapy on the Rate of Bowel Resection in Advanced Epithelial Ovarian Cancer.
    Philip CA; Pelissier A; Bonneau C; Hequet D; Rouzier R; Pouget N
    Anticancer Res; 2016 Sep; 36(9):4865-71. PubMed ID: 27630342
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Optimizing the treatment of ovarian cancer: Neoadjuvant chemotherapy and interval debulking versus primary debulking surgery for epithelial ovarian cancers likely to have suboptimal resection.
    Gill SE; McGree ME; Weaver AL; Cliby WA; Langstraat CL
    Gynecol Oncol; 2017 Feb; 144(2):266-273. PubMed ID: 27916269
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Optimal cytoreduction with neutral argon plasma energy in selected patients with ovarian and primitive peritoneal cancer.
    Renaud MC; Sebastianelli A
    J Obstet Gynaecol Can; 2013 Jan; 35(1):49-52. PubMed ID: 23343797
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A predictive score for optimal cytoreduction at interval debulking surgery in epithelial ovarian cancer: a two- centers experience.
    Ghisoni E; Katsaros D; Maggiorotto F; Aglietta M; Vaira M; De Simone M; Mittica G; Giannone G; Robella M; Genta S; Lucchino F; Marocco F; Borella F; Valabrega G; Ponzone R
    J Ovarian Res; 2018 May; 11(1):42. PubMed ID: 29843747
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Perioperative and clinical outcomes in the management of epithelial ovarian cancer using a robotic or abdominal approach.
    Feuer GA; Lakhi N; Barker J; Salmieri S; Burrell M
    Gynecol Oncol; 2013 Dec; 131(3):520-4. PubMed ID: 24080421
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.